EN DE
Watch 4DMEDICAL Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

4DMEDICAL Ltd (4DX) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of 4DMEDICAL Ltd stock A$1.28, price A$2.37, that is 46.0% below the price, quality 26 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000095416

4L 4DMEDICAL Ltd logo Thin data Nov 10, 2026

4DMEDICAL Ltd

4DX · AU
Very expensive, weak quality

Our calculation puts a fair price 46% below what the stock costs today.

Low debt
Revenue last quarter +42% vs. a year ago.
Mixed Growth (revenue 3y +114.2 %/yr in AUD)
Fair value A$1.28 · Strongly overvalued
Quality 26/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 12/100
Thin data
Estimate
Watch 4DMEDICAL Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$6.80 A$0.2300 Fair Value A$1.28 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.2300 – A$6.80 · fair‑value band A$0.9600 – A$1.60 · the A$2.37 price screens above the A$1.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow 4DMEDICAL in your weekly email

Every Wednesday you see whether 4DMEDICAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging.

Show moreShow less

It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner.

The company was incorporated in 2012 and is based in Carlton, Australia.

Stock analysis

4DMEDICAL Ltd (4DX) currently trades at A$2.37, while our estimate is A$1.28, 46% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.9600 (bear) to A$1.60 (bull), the price of A$2.37 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

4DMEDICAL Ltd reported revenue of A$7.1M in FY2026 versus A$1.1M in FY2022, a compound +60.9%/yr. Reported net income was −A$204M in FY2026.

Key figures

Market cap A$1.4B (≈ $974M) Small · EPS (TTM) A$−0.3800 · Return on equity −174% · Return on assets (EBIT) −34.3% (5-year average) · Operating margin −735% · Revenue (TTM) A$7.1M · Revenue growth (YoY) +42.3% · Free cash flow −A$32.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −46%, 4DX screens richer than that median.

Fair Value

Bear A$0.9600 Fair Value A$1.28 Bull A$1.60
Price A$2.37 · Downside -46.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 91
Debt, balance sheet and risk of trouble
Investment 12
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 59
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+20.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+114.2%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,311.2% (2021) → −813.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

4DX screens overvalued: fair value 46% below the price. Compare with Veeva Systems Inc →

Compare 4DMEDICAL Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −46.0% · Bottom 25%
Profitability
Return on assets −56.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 42.3% · Top 25%
Balance sheet
Debt / equity 0.05× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 8.32× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 13
FUTURE (revenue growth)100 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 98
DIVIDEND (yield)0 · sector 46

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs 4DX
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs 4DX
HealthEquity, Inc HQY $103.54 $112.32 +8% vs 4DX
Waystar Holding WAY $29.30 $29.10 −1% vs 4DX
Tempus AI, Inc TEM $80.54 $52.58 −35% vs 4DX
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs 4DX
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs 4DX
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs 4DX
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs 4DX
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs 4DX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

4DMEDICAL Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "4DMEDICAL Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4DX

Frequently asked questions

Is 4DMEDICAL Ltd (4DX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$1.28 versus a price of A$2.37, about 46% lower (overvalued).
What is the fair value of 4DX?
Our estimate for 4DMEDICAL Ltd is A$1.28 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$2.37.
What is the quality score of 4DX?
4DMEDICAL Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 4DMEDICAL Ltd (4DX)?
Our calculated price target is the estimate of A$1.28 (as of Nov 10, 2026). Cautious scenario A$0.9600, optimistic scenario A$1.60. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the 4DMEDICAL Ltd stock forecast for 2026?
Our estimate puts fair value at A$1.28, about 46% lower versus a price of A$2.37 (overvalued). Cautious scenario A$0.9600, optimistic scenario A$1.60. The calculation is refreshed regularly with new filings.
What is the revenue of 4DMEDICAL Ltd (4DX)?
4DMEDICAL Ltd reported trailing-twelve-month revenue of about A$7.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of 4DMEDICAL Ltd (4DX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 4DMEDICAL Ltd it is A$1.28 per share (as of Nov 10, 2026), against a price of A$2.37.
Is 4DMEDICAL Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 4DX trades above its calculated fair value: price A$2.37, fair value A$1.28, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4DX?
No. The price is what the market pays today (A$2.37); the fair value is what the company's own numbers justify (A$1.28). For 4DMEDICAL Ltd the two are A$1.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is 4DMEDICAL Ltd worth?
The market values 4DMEDICAL Ltd at about A$1.4B (market capitalisation, as of Nov 10, 2026). Per share that is A$2.37; our models calculate a fair value of A$1.28 per share.
What do the bullish and bearish scenarios say about 4DX?
Our models span a range for 4DMEDICAL Ltd: cautious scenario A$0.9600, base A$1.28, optimistic A$1.60 per share (as of Nov 10, 2026, price A$2.37). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 4DMEDICAL Ltd (4DX)?
Balance-sheet figures for 4DMEDICAL Ltd (as of Nov 10, 2026): return on equity −174.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 4DX from its 52-week high?
4DMEDICAL Ltd trades at A$2.37, about 65% below its 52-week high of A$6.80 and 66% above the low of A$1.43 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$1.28 is for.
Which stocks are comparable to 4DMEDICAL Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 4DMEDICAL Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$2.37, calculated fair value A$1.28 (−46%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. 4DMEDICAL Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 4DMEDICAL Ltd (4DX)?
The closing price on Nov 11, 2026 was A$2.37. Our estimate is A$1.28, about 46% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 4DMEDICAL Ltd right now?
The price sits above even our optimistic bull case (A$1.60). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of 4DMEDICAL Ltd

How large is the market capitalisation of 4DMEDICAL Ltd (4DX)?
The market capitalisation of 4DMEDICAL Ltd is A$1.4B (≈ $974M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of 4DMEDICAL Ltd (4DX)?
Earnings per share at 4DMEDICAL Ltd are A$−0.3800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of 4DMEDICAL Ltd (4DX)?
The return on equity (ROE) of 4DMEDICAL Ltd is −174% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 4DMEDICAL Ltd (4DX)?
On an EBIT basis the return on assets of 4DMEDICAL Ltd is −34.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 4DMEDICAL Ltd (4DX)?
The operating margin of 4DMEDICAL Ltd is −735% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 4DMEDICAL Ltd (4DX)?
Revenue at 4DMEDICAL Ltd is growing +42.3% versus a year earlier (3y avg +114%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 4DMEDICAL Ltd (4DX) generate?
The free cash flow of 4DMEDICAL Ltd is −A$32.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does 4DMEDICAL Ltd (4DX) hold?
4DMEDICAL Ltd holds more cash than debt, A$275M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch 4DMEDICAL Ltd in the live analysis

One click puts 4DMEDICAL Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.